| P2093 | author name string | Jari E Heikkilä | |
| | Ari E Hinkkanen | |
| | Markus J V Vähä-Koskela | |
| P2860 | cites work | Metapopulation dynamics and spatial heterogeneity in cancer | Q24538673 |
| | Fever therapy revisited | Q24650460 |
| | Intergeneric poliovirus recombinants for the treatment of malignant glioma | Q24682902 |
| | Canine parvovirus-like particles, a novel nanomaterial for tumor targeting | Q25256822 |
| | Mathematical modeling of tumor therapy with oncolytic viruses: regimes with complete tumor elimination within the framework of deterministic models | Q25257260 |
| | Avian Reoviruses Cause Apoptosis in Cultured Cells: Viral Uncoating, but Not Viral Gene Expression, Is Required for Apoptosis Induction | Q27473517 |
| | Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers | Q28144562 |
| | Oncolytic herpes simplex virus vectors for cancer virotherapy | Q28202611 |
| | Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1) | Q28203950 |
| | Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase | Q28204166 |
| | LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 | Q28210584 |
| | OBSERVATIONS ON THE REPEATED ADMINISTRATION OF VIRUSES TO A PATIENT WITH ACUTE LEUKEMIA. A PRELIMINARY REPORT. | Q43786318 |
| | Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models | Q44012459 |
| | Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. | Q44017743 |
| | Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid | Q44135421 |
| | In vivo antitumor activity of Sindbis viral vectors | Q44149697 |
| | Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints | Q44203789 |
| | Influenza immunisation in children with solid tumours | Q44222857 |
| | In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy | Q44269918 |
| | Acquired resistance to cytolysis of the E1B-attenuated adenovirus, dl1520, in ovarian tumour cell lines | Q44519492 |
| | In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. | Q44543288 |
| | Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. | Q44729128 |
| | Influenza virus infection of transplanted tumors. I. Multiplication of a neurotropic strain and its effect on solid neoplasms. | Q44736815 |
| | Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma | Q44948301 |
| | Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer | Q45071436 |
| | Cancer cells as targets for lentivirus-mediated gene transfer and gene therapy. | Q45152963 |
| | Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector | Q45419303 |
| | Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells | Q45447061 |
| | Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses | Q45520731 |
| | Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer | Q45638675 |
| | Inhibition of growth of five transplantable mouse tumors by the virus of Russian Far East encephalitis | Q45689498 |
| | NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT. | Q45713156 |
| | Pathogenicity and oncolytic capacity of RI virus strain RI-67 in man. | Q45720375 |
| | Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene--a phase I/II clinical protocol. | Q45721971 |
| | Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. | Q45722656 |
| | Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme | Q45723594 |
| | Intraperitoneal therapy of ovarian cancer using an engineered measles virus. | Q45731301 |
| | The complement response against an oncolytic virus is species-specific in its activation pathways | Q45733626 |
| | Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles | Q45734185 |
| | A genetically engineered influenza A virus with ras-dependent oncolytic properties | Q45734706 |
| | Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment | Q36412199 |
| | Genotoxicity of retroviral integration in hematopoietic cells. | Q36453658 |
| | Oncolytic adenoviruses as antiglioma agents | Q36499227 |
| | A model for tumor suppression using H-1 parvovirus | Q36547966 |
| | Evidence accumulating in support of cancer vaccines combined with chemotherapy: a pragmatic review of past and present efforts. | Q36590513 |
| | The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro | Q36612425 |
| | Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice | Q36654496 |
| | Spontaneous curing of a minute virus of mice carrier state by selection of cells with an intracellular block of viral replication | Q36860693 |
| | Persistent infection of some standard cell lines by lymphocytic choriomeningitis virus: transmission of infection by an intracellular agent | Q36908988 |
| | Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells | Q37116149 |
| | The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors | Q37247954 |
| | Viruses as an aid to cancer therapy: regression of solid and ascites tumors in rodents after treatment with bovine enterovirus | Q37473930 |
| | Plasmoviruses: nonviral/viral vectors for gene therapy. | Q37631837 |
| | Specific oncolytic activity of herpesvirus saimiri in pancreatic cancer cells. | Q38275092 |
| | Is there a relationship between influenza vaccinations and risk of melanoma? A population-based case-control study | Q39223277 |
| | The selection of virus-resistant Chinese hamster ovary cells | Q40006902 |
| | Viral oncolysate in the management of malignant melanoma.I. Preparation of the oncolysate and measurement of immunologic responses | Q40089626 |
| | Viral oncolysate in the management of malignant melanoma. II. Clinical studies | Q40089633 |
| | Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. | Q40213652 |
| | Replication-deficient rSV40 mediate pancreatic gene transfer and long-term inhibition of tumor growth | Q40228737 |
| | Exhaustion of type I interferon response following an acute viral infection | Q40241597 |
| | Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. | Q40248498 |
| | Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice | Q40254012 |
| | The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer | Q40262890 |
| | Recombinant baculovirus containing the diphtheria toxin A gene for malignant glioma therapy | Q40272768 |
| | Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death | Q40277603 |
| | AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma | Q40297313 |
| | A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus | Q40298957 |
| | Oncolysis of pancreatic tumour cells by a gamma34.5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway | Q40300876 |
| | An adenovirus serotype 5 vector with fibers derived from ovine atadenovirus demonstrates CAR-independent tropism and unique biodistribution in mice | Q40308939 |
| | Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice | Q40312249 |
| | Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus | Q40314091 |
| | Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector. | Q40321998 |
| | Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter | Q40329170 |
| | The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. | Q40355254 |
| | Bovine herpesvirus 4 induces apoptosis of human carcinoma cell lines in vitro and in vivo. | Q40360887 |
| | Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice | Q40365702 |
| | Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination | Q40379092 |
| | A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy | Q40395135 |
| | Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas | Q40407903 |
| | Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain | Q40408773 |
| | Selective cytolysis of tumor cells by mumps virus S79. | Q40409461 |
| | Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency | Q40411792 |
| | Experimental therapy of allogeneic solid tumors induced in athymic mice with suicide gene-transducing replication-competent foamy virus vectors | Q40419693 |
| | Enhanced gene transfer activity of peptide-targeted gene-delivery vectors | Q40431364 |
| | Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer | Q40440806 |
| | Avian adenovirus vector CELO-TK displays anticancer activity in human cancer cells and suppresses established murine melanoma tumors. | Q40447916 |
| | Oncolysis of human ovarian cancers by echovirus type 1. | Q40462464 |
| | Transduction of human glial and neuronal tumor cells with different lentivirus vector pseudotypes. | Q40468040 |
| | Effects of febrile temperature on adenoviral infection and replication: implications for viral therapy of cancer. | Q40481068 |
| | Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme | Q40495113 |
| | Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector | Q40515045 |
| | Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer | Q40515050 |
| | Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein | Q40515535 |
| | Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus | Q40519641 |
| | Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus | Q40526582 |
| | An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism | Q40548373 |
| | Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer | Q40559120 |
| | Xenograft models for liver metastasis: Relationship between tumor morphology and adenovirus vector transduction | Q40560870 |
| | Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases | Q40566666 |
| | Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats | Q40577228 |
| | Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer | Q40608630 |
| | Experimental treatment of human neuroblastoma using live-attenuated poliovirus | Q40610616 |
| | Systemic tumor targeting and killing by Sindbis viral vectors | Q40612706 |
| | The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. | Q40619723 |
| | A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer | Q40624035 |
| | Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression | Q40626041 |
| | Transient suppression of transgene expression by means of antisense oligonucleotides: a method for the production of toxin-transducing recombinant viruses | Q40739624 |
| | New developments in the virus therapy of cancer: a historical review | Q40745867 |
| | Controlled cell killing by a recombinant nonsegmented negative-strand RNA virus. | Q40749929 |
| | RNA replicons derived from poliovirus are directly oncolytic for human tumor cells of diverse origins. | Q40765369 |
| | Viral oncolysates in patients with advanced ovarian cancer | Q40787940 |
| | Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials | Q40790899 |
| | Expansion of tropism of a feline parvovirus to target a human tumor cell line by display of an alpha(v) integrin binding peptide on the capsid | Q40811135 |
| | Antitumor properties of influenza virus vectors. | Q40832610 |
| | Adenovirus-mediated transfer of p53 and Fas ligand drastically enhances apoptosis in gliomas | Q40877048 |
| | Tumor-selective gene transduction and cell killing with an oncotropic autonomous parvovirus-based vector | Q40878212 |
| | Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth | Q40889306 |
| | Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma | Q40988275 |
| | Destruction of tumour cells by Rift Valley fever virus | Q41032454 |
| | Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. | Q41082105 |
| | Constitutive activation of U937 promonocytic cell clones selected for their resistance to parvovirus H-1 infection | Q41125265 |
| | Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum | Q41192433 |
| | Growth properties of a human melanoma cell line are altered by adeno-associated parvovirus type 2. | Q41379820 |
| | Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors | Q41494111 |
| | Endogenous inhibitors of the dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-transformed cells | Q41503444 |
| | Treatment of human cancer with mumps virus | Q42439769 |
| | Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin | Q42515334 |
| | Potentiated gene delivery to tumors using herpes simplex virus/Epstein-Barr virus/RV tribrid amplicon vectors | Q42800702 |
| | Replicative retroviral vectors for cancer gene therapy | Q42807227 |
| | Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L. | Q42807639 |
| | Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. | Q42820783 |
| | Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus | Q42977068 |
| | Coxsackievirus B-3 selection of virus resistant Buffalo green monkey kidney cells and chromosome analysis of parental and resistant cells | Q43445420 |
| | Differing responses of hamsters to infection by vesicular stomatitis virus Indiana and New Jersey serotypes | Q43466858 |
| | Virus treatment in advanced cancer; a pathological study of fifty-seven cases | Q43484945 |
| | Epidemiology and outcomes of serious influenza-related infections in the cancer population | Q43490574 |
| | The virus of Venezuelan equine encephalomyelitis as an antineoplastic agent in man. | Q43503627 |
| | Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. | Q43583253 |
| | Specific tumor-cell killing with adenovirus vectors containing the apoptin gene | Q43668971 |
| | Nonrandom chromosome aberrations and clonal populations in head and neck cancer | Q72309636 |
| | Regression of Hodgkin's disease after measles | Q72470432 |
| | Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in DNA replication, repair, and stress response | Q73034107 |
| | Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy | Q73302908 |
| | Factors regulating tumor pressure in hepatocellular carcinoma and implications for tumor spread | Q73574952 |
| | Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses | Q74139493 |
| | Oncotic pressure in solid tumors is elevated | Q74181161 |
| | Viral agents oncolytic for human tumors in heterologous host; oncolytic effect of Coxsackie B viruses | Q74428030 |
| | Note on the experimental use of rabies vaccine for melanomatosis | Q75449355 |
| | Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer | Q78392743 |
| | Systemic reovirus therapy of metastatic cancer in immune-competent mice | Q78835027 |
| | A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229) | Q79791348 |
| | Why we're losing the war on cancer (and how to win it) | Q79887613 |
| | Cancer immunotherapy | Q80066933 |
| | Rescue and propagation of fully retargeted oncolytic measles viruses | Q81348398 |
| | Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer | Q81476542 |
| | Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration | Q45735369 |
| | Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice | Q45737116 |
| | Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. | Q45737842 |
| | Combined effects of adeno-associated virus vector and a herpes simplex virus mutant as neoplastic therapy | Q45740952 |
| | Cooperation of B cells and T cells is required for survival of mice infected with vesicular stomatitis virus | Q45758771 |
| | Novel infectious particles generated by expression of the vesicular stomatitis virus glycoprotein from a self-replicating RNA. | Q45782478 |
| | Minute virus of mice inhibits cell transformation by simian virus 40 | Q45799432 |
| | Virus-specific effects of interferon in embryonal carcinoma cells | Q45805862 |
| | Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant | Q45854779 |
| | Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model | Q45854903 |
| | Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. | Q45856129 |
| | Intracerebral injection of adenovirus harboring the HSVtk gene combined with ganciclovir administration: toxicity study in nonhuman primates | Q45858203 |
| | A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model | Q45858715 |
| | Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. | Q45859438 |
| | Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy | Q45863191 |
| | Newcastle disease virus selectively kills human tumor cells | Q45865340 |
| | A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds. | Q45872992 |
| | Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors | Q45875050 |
| | A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate | Q45875393 |
| | Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models. | Q45877979 |
| | Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus | Q45878208 |
| | Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture | Q45880536 |
| | Anticancer effect of a lentiviral vector capable of expressing HIV-1 Vpr. | Q45881419 |
| | Rapid functional exhaustion and deletion of CTL following immunization with recombinant adenovirus | Q45882587 |
| | Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody | Q45882951 |
| | Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results | Q45883534 |
| | The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells | Q45888974 |
| | Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection | Q46167187 |
| | Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy | Q46267591 |
| | Tumor size at the time of adoptive transfer determines whether tumor rejection occurs | Q47238642 |
| | Development and biological properties of a new live attenuated mumps vaccine | Q48562401 |
| | Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells | Q48587406 |
| | Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers. | Q50768483 |
| | A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. | Q52537791 |
| | The interaction between host-supplied connective tissue and xenografted human tumor cells. | Q53035117 |
| | MTH-68/H oncolytic viral treatment in human high-grade gliomas. | Q53347956 |
| | Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells. | Q53603657 |
| | Mouse parvovirus infection potentiates rejection of tumor allografts and modulates T cell effector functions. | Q54208621 |
| | Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. | Q55473726 |
| | Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents | Q64377634 |
| | Age-dependent effects of repeated immunization with a first generation adenovirus vector on the immune response and transgene expression in young and old rats | Q64378571 |
| | Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases | Q64379110 |
| | Induced apoptosis supports spread of adenovirus vectors in tumors | Q64379697 |
| | Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved--deletion of the viral E1b-19-kD gene increases the viral oncolytic effect | Q64379701 |
| | An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy | Q64380394 |
| | Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance | Q67297922 |
| | Immunotherapy of advanced gynecologic cancer patients utilizing mumps virus | Q70062831 |
| | Methods of active immunotherapy and viral oncolysis in some forms of cancer | Q70143154 |
| | A poliovirus-susceptible transgenic mouse model as a possible replacement for the monkey neurovirulence test of oral poliovirus vaccine | Q71721245 |
| | Drug penetration in solid tumours | Q29614404 |
| | A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. | Q32016260 |
| | Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors | Q32125078 |
| | Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity | Q33202718 |
| | DNA vaccines based on chimeric potyvirus-like particles carrying HPV16 E7 peptide (aa 44-60). | Q33222814 |
| | Enhanced baculovirus-mediated transduction of human cancer cells by tumor-homing peptides | Q33246815 |
| | Characterization of the lymphotropic amplicons-6 and tamplicon-7 vectors derived from HHV-6 and HHV-7. | Q33247327 |
| | Tumor specific phage particles promote tumor regression in a mouse melanoma model. | Q33257201 |
| | Mathematical modeling of tumor therapy with oncolytic viruses: effects of parametric heterogeneity on cell dynamics | Q33259239 |
| | In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. | Q33328885 |
| | Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential | Q33780536 |
| | Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway | Q33785311 |
| | The herpes simplex virus gE-gI complex facilitates cell-to-cell spread and binds to components of cell junctions | Q33785316 |
| | Vaccination against human cancers (review). | Q33796713 |
| | Genetic instability and darwinian selection in tumours | Q33804007 |
| | Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant | Q33804845 |
| | Efficacy, safety, and cost of new anticancer drugs | Q33811454 |
| | Newcastle disease virus (NDV): brief history of its oncolytic strains | Q33841589 |
| | Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease | Q33846198 |
| | Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy | Q33847896 |
| | Parvovirus nonstructural proteins induce an epigenetic modification through histone acetylation in host genes and revert tumor malignancy to benignancy | Q33884051 |
| | Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial | Q33905053 |
| | Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus | Q33908950 |
| | a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer | Q33912833 |
| | Bovine enterovirus as an oncolytic virus: foetal calf serum facilitates its infection of human cells | Q33959637 |
| | Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture | Q33968768 |
| | Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats | Q34092661 |
| | Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors | Q34169782 |
| | ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties | Q34178661 |
| | Delivery of molecular and cellular medicine to solid tumors | Q34190339 |
| | The spontaneous regression of cancer. A review of cases from 1900 to 1987. | Q34230803 |
| | Studies on the use of viruses in the treatment of carcinoma of the cervix | Q34240325 |
| | VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents | Q34273164 |
| | Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. | Q34291195 |
| | Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. | Q35945465 |
| | Vesicular stomatitis virus as an oncolytic vector | Q36020593 |
| | What they are, how they work and why they do what they do? The story of SV40-derived gene therapy vectors and what they have to offer | Q36107577 |
| | Adeno-associated virus vectors: potential applications for cancer gene therapy | Q36165834 |
| | Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production. | Q36186475 |
| | Vaccines against human papillomavirus and cervical cancer: promises and challenges | Q36217993 |
| | Gene therapy for malignant glioma: current clinical status | Q36226708 |
| | Mechanisms of tumor evasion. | Q36280061 |
| | HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy | Q36297792 |
| | Recent progress in the battle between oncolytic viruses and tumours | Q36315580 |
| | Oncolytic adenoviruses - selective retargeting to tumor cells | Q36318189 |
| | Oncolytic viral therapies - the clinical experience | Q36318202 |
| | Virus inoculation in mice bearing Ehrlich ascitic tumors: antigen production and tumor regression | Q36328381 |
| | Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression | Q36347549 |
| | Cancer-selective therapy of the future: apoptin and its mechanism of action | Q36367389 |
| | Development of the PANVAC-VF vaccine for pancreatic cancer | Q36383786 |
| | Herpesvirus saimiri-based gene delivery vectors | Q36395597 |
| | Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. | Q34294068 |
| | Replication-selective virotherapy for cancer: Biological principles, risk management and future directions | Q34297058 |
| | Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. | Q34334845 |
| | Foamy virus vector integration sites in normal human cells | Q34334976 |
| | Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease | Q34357917 |
| | Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice | Q34371450 |
| | Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. | Q34416019 |
| | Not all viruses are bad guys: the case for reovirus in cancer therapy | Q34428090 |
| | Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies | Q34437238 |
| | Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma | Q34463785 |
| | Reovirus therapy of tumors with activated Ras pathway | Q34479740 |
| | Immunosuppression promotes reovirus therapy of colorectal liver metastases | Q34502982 |
| | Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. | Q34508425 |
| | Impact of vaccinations and infectious diseases on the risk of melanoma--evaluation of an EORTC case-control study | Q34542560 |
| | Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients | Q34553710 |
| | Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. | Q34556808 |
| | Lymphoma cell apoptosis in the liver induced by distant murine cytomegalovirus infection | Q34647659 |
| | Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines | Q34648125 |
| | Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis | Q34659721 |
| | Immune escape of tumors: apoptosis resistance and tumor counterattack. | Q34671704 |
| | Studies on the use of mumps virus for treatment of human cancer | Q34719177 |
| | Advances in the development of non-human viral DNA-vectors for gene delivery | Q34729612 |
| | Adenoviral vectors: systemic delivery and tumor targeting | Q35043111 |
| | Gene and cancer therapy--pseudorabies virus: a novel research and therapeutic tool? | Q35090827 |
| | Measles Infection of the Central Nervous System | Q35112035 |
| | Common community respiratory viruses in patients with cancer: more than just "common colds". | Q35122262 |
| | Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas | Q35216380 |
| | Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus | Q35571573 |
| | Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses | Q35610303 |
| | Oncolytic viral therapy and immunotherapy of malignant brain tumors: two potential new approaches of translational research. | Q35682205 |
| | Replicative oncolytic herpes simplex viruses in combination cancer therapies | Q35698645 |
| | Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development | Q35761426 |
| | Genetically modified adenoviruses against gliomas: from bench to bedside | Q35860372 |
| | Cancer gene therapy through autonomous parvovirus--mediated gene transfer | Q35895793 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | oncolytic virus | Q1560099 |
| P304 | page(s) | 178-216 | |
| P577 | publication date | 2007-03-23 | |
| P1433 | published in | Cancer Letters | Q326372 |
| P1476 | title | Oncolytic viruses in cancer therapy | |
| P478 | volume | 254 | |